Virtual Library
Start Your Search
P. Van Schil
Moderator of
-
+
Imaging and locally advanced NSCLC (ID 41)
- Event: ELCC 2017
- Type: Poster Discussion session
- Track:
- Presentations: 9
- Moderators:H. Prosch, S. Senan, P. Van Schil
- Coordinates: 5/06/2017, 14:45 - 15:45, Room W
-
+
Invited Discussant 45PD and 46PD (ID 529)
14:45 - 15:45 | Author(s): H. Prosch
- Abstract
Abstract not provided
-
+
Invited Discussant 61PD and 72PD (ID 530)
14:45 - 15:45 | Author(s): P. Van Schil
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Invited Discussant 73PD and 74PD (ID 531)
14:45 - 15:45 | Author(s): S. Senan
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
- Abstract
Background:
Integrated 18F-FDG, PET-CT has shown somewhat variable sensitivity and specificity for nodal staging in tuberculosis endemic areas. This variation is mainly because PET scans show falsely increased 18F-FDG uptake in inflammatory nodes, which may be observed in lymph nodes containing calcification or showing higher attenuations than those of surrounding vessels on unenhanced CT scans. The AIM of the study was to evaluate the efficacy of PET-CT for mediastinal nodal staging in non-small cell lung cancer (NSCLC) patients in a tuberculosis-endemic country.
Methods:
From February 2012 to February 2016, a total of 160 patients underwent surgery for pathologically proven NSCLC. Patients who received neoadjuvant treatment were excluded from the study. Assessment of the diagnostic efficacy of integrated PET- CT for detecting nodal metastasis was performed in 46 patients (Male to Female ratio:4; mean age- 55 years). Patients underwent an integrated PET/CT examination and subsequent surgical nodal staging. Nodes showing greater 18F-FDG uptake at PET without benign calcification or high attenuation >70 household unit (HU) at unenhanced CT were regarded as being positive for malignancy. All patients underwent hilar and mediastinal lymph node dissection according to the AJCC lymph node map after resection of the main tumour. The histologic nodal assessment results were used as reference standards. Of these 46 patients, 10 (20%) had a past medical history of pulmonary tuberculosis as determined by clinical or imaging studies.
Results:
A total of 230 mediastinal nodal stations were evaluated in 46 patients; 5 (2%) stations in 4 (8%) patients proved to be malignant by histopathology. Mean number of lymph node stations were 5. On a per-nodal station basis, PET CT for mediastinal lymph nodes staging has sensitivity: 60%; specificity: 97%; accuracy: 96%; positive predictive value (PPV): 38%; negative predictive value (NPV): 99%.
Conclusions:
Integrated PET-CT provides high specificity and high accuracy, but low sensitivity for mediastinal staging of NSCLC. The high specificity is achieved at the expense of sensitivity by interpreting calcified nodes or nodes with high attenuation at CT, even with high FDG uptake at PET, as benign in a tuberculosis-endemic region.
Clinical trial identification:
Legal entity responsible for the study:
Dr. Bhim Rao Ambedkar Institute Rotary Cancer Hospital, All India Institute Medical Sciences, New Delhi
Funding:
Dr. Bhim Rao Ambedkar Institute Rotary Cancer Hospital, All India Institute Medical Sciences, New Delhi
Disclosure:
All authors have declared no conflicts of interest.
-
+
46PD - The solid component evaluated on computed tomography can predict the invasiveness and lymph node metastasis in lung adenocarcinoma as well as pathological invasive size (ID 248)
14:45 - 15:45 | Author(s): Y. Sakao, H. Kuroda, T. Mizuno, N. Sakakura, Y. Yatabe
- Abstract
Background:
The newly revised TNM classification shows that cT and pT are to be evaluated with solid component on CT and pathological invasive size in adenocarcinoma of the lung. We evaluated the predictive factors for invasiveness, lymph node metastasis and recurrence in patients with adenocarcinomas of the lung, particularly pathological tumor diameters both of gross and invasive size, and solid component diameter using computed tomography (CT) both with lung window settings and mediastinal window settings.
Methods:
We evaluated 533 patients with lung adenocarcinomas (diameter, 6–132 mm) who underwent surgical resections. 447 of the 533 have been underwent systematic node dissection. Tumors were examined using CT with thin section conditions (1.25-mm thick: high-resolution CT), with tumor dimensions evaluated under two conditions: lung window (LD) and mediastinal window (MD) settings. Both of the tumor size on CT (LD, MD), consolidation component size on CT with lung window settings (C), preoperative serum carcinoembryonic antigen (CEA) levels, pathological tumor diameter both of gross(GS) and invasive lesion(IS), and pathological status [invasion of lymphatic vessels (ly), vascular vessels (v), pleura (pl), lymph node metastasis] were examined. Area under the curve (AUC) of Receiver Operating Characteristic (ROC) was used for evaluation.
Results:
AUCs according to the variables.rnTable: 46PDrnrn
rnGS: pathological gross tumor size, IS: Pathological invasive size, LD: Diameter with lung window settings on CT, MD: diameter with mediastinal window settings on CT, C: consolidation diameter with lung window settings on CT.rnrn rnrnVariables rnly(N = 533) rnv(N = 533) rnpl (N = 533) rnLymph node metastasis (N = 447) rnRecurrence (N = 447) rnCorrelation coefficient IS and other variables rnrn rnGS rn0.73 rn0.71 rn0.72 rn0.72 rn0.83 rnN.A rnrn rnIS rn0.86 rn0.82 rn0.79 rn0.79 rn0.86 rnN.A rnrn rnLD rn0.71 rn0.70 rn0.70 rn0.71 rn0.79 rn0.65 rnrn rnMD rn0.87 rn0.82 rn0.81 rn0.80 rn0.85 rn0.80 rnrn rnC rn0.83 rn0.80 rn0.79 rn0.79 rn0.83 rn0.78 rnrn rnC/LD rn0.81 rn0.78 rn0.75 rn0.73 rn0.69 rnN.A rnrn rnrnCEA rn0.68 rn0.66 rn0.69 rn0.70 rn0.72 rnN.A rn
Conclusions:
The solid component evaluated on computed tomography especially by MD and C can predict the invasiveness and lymph node metastasis in lung adenocarcinoma as well as pathological invasive size.
Clinical trial identification:
N.A.
Legal entity responsible for the study:
Yukinori Sakao
Funding:
N/A
Disclosure:
All authors have declared no conflicts of interest.
-
+
- Abstract
Background:
The presence of solid histologic pattern in lung adenocarcinoma (ADC) is associated with early recurrence. However, individualized prognosis in patients with solid component is still unclear. This study aimed to develop a nomogram predicting the recurrence probability in stage I lung ADC patients with solid component.
Methods:
A total of 5904 patients with stage I lung ADC who underwent curative surgical resection from January 2008 through December 2014 at Shanghai Chest Hospital were retrospectively reviewed. Tumors were subtyped by using the IASCL/ATS/ERS classification. Of these patients, 708 contained a solid component. Prognostic value of gender, age at diagnosis, smoking history, operation type, tumor location, tumor size, pathological subtype, cell differentiation, lymphovascular and visceral pleural invasion were investigated. Multivariate Cox regression analysis of recurrence-free survival (RFS) in patients with solid component was performed and a nomogram to predict RFS was constructed. The nomogram was internally validated.
Results:
The overall recurrence rate in patients with solid component was 25.0% (177/708), with predominant solid subtype and minor solid component in 49.2% (87/177) and 50.8% (90/177) of cases, respectively. Larger tumor size (P = 0.002), predominant solid component (P = 0.003), advanced age at diagnosis (P = 0.015), and visceral pleural invasion (P = 0.040) were associated with an increased risk of recurrence and were included in the nomogram. The predictive model had a concordance index of 0.643 (95% confidence interval, 0.601-0.685) and showed good calibration.
Conclusions:
The nomogram model including identified risk factors for RFS is applicable in treatment decision-making for early stage lung ADC with pathological solid component. External validation is required to recommend this nomogram in routine practice.
Clinical trial identification:
Legal entity responsible for the study:
Shanghai Chest Hospital
Funding:
Shanghai Chest Hospital
Disclosure:
All authors have declared no conflicts of interest.
-
+
72PD - Video-Assisted Thoracic Surgery (VATS) lobectomy for non-small cell lung cancer after induction chemotherapy: A propensity score-matched analysis on behalf of the Italian VATS group (ID 255)
14:45 - 15:45 | Author(s): L. Bertolaccini, A. Pardolesi, D. Argnani, J. Brandolini, D. Divisi, A. Bertani, A. Droghetti, A. Gonfiotti, R. Crisci, P. Solli
- Abstract
Background:
The aim of the present study was to assess outcomes among non-small cell lung cancer (NSCLC) patients treated with preoperative chemotherapy followed by Video-Assisted Thoracic Surgery (VATS) lobectomy from a National multi-institutional Registry.
Methods:
A National Registry established in 2013 was used to collect data from 65 Thoracic Surgery Units (>3,700 patients enrolled); only information from Units with >100 VATS lobectomies enrolled were analysed. A retrospective analysis was performed on patients with NSCLC who received preoperative chemotherapy followed VATS lobectomy within one year and compared to a propensity score matched population without preoperative chemotherapy. Propensity score (greedy 5 to 1 digit matching algorithm) estimated with multiple logistic regressions based on selection bias and potential confounding variables produced 221 patients (control group). After propensity score matching, data were compared with the paired Student’s t-test, Pearson’s χ[2] and Fisher’s exact test. Differences were considered to be statistically significant when the p - value was <0.05.
Results:
56/1679 (3.34%) patients met study inclusion criteria. There were no significant differences in baseline characteristics between groups (Table 1a). The majority of patients were clinical stage IIIA, although a small percentage of clinical stage II patients had preoperative therapy. Anatomic distribution of lobectomies and the number of resected lymph nodes not significantly differed between groups. Table 1b presents postoperative histology in the neoadjuvant groups. Table 1c reports short-term perioperative outcomes. No perioperative mortality was recorded in both groups. Overall morbidity (pneumonia, atrial fibrillation) was significantly higher in the neoadjuvant group, but interestingly, all the other variables were not influenced (conversion rate, operative time, blood loss, air leak duration, length of stay).rnTable: 72PDDemographics, postoperative histology/stage of the neoadjuvant group, and selected perioperative/postoperative outcomes. NA = not applicable, SD = standard deviationrnrn
rnrn rnTable 1a. Demographics characteristics rnrn rnrnCharacteristics rnNeoadjuvant Group (N = 56) rnPropensity Matched Group (N = 221) rnp - value rnrn rnM/F (%) rn50 rn61.99 rn0.938 rnrn rnAge (mean ± SD) rn64.14 ± 10.64 rn67.44 ± 11.93 rn0.888 rnrn rnCharlson Index (mean ± SD) rn4.19 ± 1.75 rn4.43 ± 1.85 rn0.530 rnrn rnECOG score rn0 rn0 rnNA rnrn rnPreoperative stage (N, %) • IIA • IIB • IIIA rn13 (23.21) 18 (32.14) 25 (44.64) rn64 (28.96) 59 (26.70) 98 (44.34) rn0.877 0.568 0.964 rnrn rnSurgical procedure (N, %) • Left upper lobectomy • Left lower lobectomy • Right upper lobectomy • Right lower lobectomy • Lower bilobectomy rn8 (14.29) 10 (17.86) 25 (44.64) 12 (21.43) 1 (1.79) rn43 (19.46) 29 (13.12) 89 (40.27) 36 (16.29) 3 (1.36) rn0.808 0.124 0.628 0.663 0.882 rnrn rnrnrn rn
rnrn rnrnTable 1b. Postoperative histology and stage of the Neoadjuvant Group (N, %) rnrn rnPostoperative histology • Adenocarcinoma • Squamous cell carcinoma • Other rn25 (44.64) 12 (21.43) 21 (37.5) rnrn rnStage • IA • IB • IIA • IIB • IIIA rn7 (12.5) 12 (21.43) 22 (39.29) 1 (1.79) 14 (25) rnrn rnrnrn rn
rnrn rnTable 1c. Selected perioperative and postoperative outcomes rnrn rnrnCharacteristics rnNeoadjuvant Group (n = 56) rnPropensity Matched Group (n = 221) rnp - value rnrn rnDuration of surgical operation, minutes (mean ± SD) rn182.14 ± 65.69 rn182.76 ± 66.17 rn0.933 rnrn rnIntraoperative blood loss, mL (mean ± SD) rn148.93 ± 153.57 rn154.19 ± 126.09 rn0.163 rnrn rnResected lymph nodes (mean ± SD) rn17.54 ± 10.37 rn14.04 ± 7.65 rn0.890 rnrn rnOverall conversion to thoracotomy (N, %) • Lymph nodes on pulmonary artery • Anomalies of anatomy • Bleeding rn6 (10.71) 3 (5.36) 1 (1.79) 2 (3.57) rn20 (9.05) 11 (4.98) 1 (0.45) 8 (3.62) rn0.0634 0.193 0.517 0.195 rnrn rnPostoperative air leaks (N, %) rn6 (10.71) rn12 (5.43) rn0.0396 rnrn rnPostoperative complications (N, %) • Pneumonia • Atrial fibrillation rn6 (10.71) 4 (7.14) rn7 (3.17) 10 (4.52) rn0.0398 0.0419 rnrn rnHospital length of stay, days (mean ± SD) rn8.73 ± 6.60 rn9.54 ± 8.92 rn0.759 rnrn rnrnrn
Conclusions:
VATS lobectomy after induction chemotherapy in stage II/IIIA NSCLC is feasible with a favourable profile regarding overall morbidity and mortality. This preliminary report shows that neoadjuvant treatment may not represent per se a contraindication to the VATS approach.
Clinical trial identification:
Legal entity responsible for the study:
Italian VATS Group
Funding:
Italian VATS Group
Disclosure:
All authors have declared no conflicts of interest.
-
+
73PD - Prognostic value of pre- to post-treatment primary tumor metabolic volume reduction on 18F-FDG-PET/CT in a patient cohort with inoperable locally-advanced NSCLC treated with definitive chemoradiotherapy (ID 294)
14:45 - 15:45 | Author(s): O. Roengvoraphoj, C. Eze, W. Fendler, M. Dantes, C. Belka, F. Manapov
- Abstract
Background:
Previous studies have shown that primary tumor metabolic volume (PT-MV) on 18F-FDG-PET/CT could serve as a prognostic factor in patients treated with definitive chemoradiotherapy (CRT). We analyzed a correlation between pre- to posttreatment PT-MV reduction during the course of CRT and overall survival.
Methods:
Sixty-five patients with histologically confirmed NSCLC IIIA-B, treated with definitive CRT in the sequential (21/65 pts, 32.3%) or concurrent (44/65 pts, 67.7%) mode, who underwent 18F-FDG-PET/CT before and about 4-6 weeks after the CRT, were analyzed. Histology yielded 22 (33.8%) adenocarcinomas, 34 (52.3%) squamous cell carcinomas, 8 (12.3%) large-cell carcinomas and 1(1.5%) NSCLC not otherwise specified (NOS). Thirty-five patients (35/65, 53%) were enrolled in randomized clinical trials (16 pts in GILT, 10 pts in InCoDor and 9 pts in BROCAT study CTRT 99/97). The most common concurrent chemotherapy regimen (18/65 pts, 27.7%) consisted of cisplatin given intravenously at a dose of 20mg/m[2] on days 1-4 and oral vinorelbine 50mg/m[2] on days 1, 8 and 15, every 4 weeks for two courses.
Results:
Median OS for the entire cohort was 16 months (95% [CI],11.5–20.5). Complete remission (CR) was reached in 20 (31%), whereas partial and non-response occurred in 31 (48%) and 14 (22%) patients, respectively. The mean change from pre- to posttreatment PT-MV was -51% (range: +125% to -100%). Various cutoffs of PT-MV reduction (100- 90-85-80-70-60 and 50%) after the CRT were analyzed. CR(n = 20) had a median OS of 26 (95 CI: 5-47) vs. 13 months (95 CI:9-16) observed in the rest of treated group (p = 0.01, log-rank test). The results also showed a significant difference in OS favoring patients with PT-MV reduction >90% (n = 18) vs. the rest with a median survival of 24 vs. 13 months, respectively (p = 0.04, log-rank test). However, the association between PT-MV reduction at 80% and 70% and survival showed borderline significance (p = 0.07 and 0.09, log-rank test). PT-MV reduction at 60 and 50% failed to show an effect on OS.
Conclusions:
In this inoperable locally-advanced NSCLC cohort, a PT-MV reduction of at least 90% after definitive CRT correlated with improved OS.
Clinical trial identification:
Legal entity responsible for the study:
Deparment of Radiation Oncology, LMU Munich
Funding:
N/A
Disclosure:
All authors have declared no conflicts of interest.
-
+
74PD - Radiation-induced lung toxicity prediction modeling in NSCLC: Importance of baseline toxicity scoring (ID 506)
14:45 - 15:45 | Author(s): G. Defraene, W. Van Elmpt, D. De Ruysscher
- Abstract
Background:
Validated outcome prediction models with high discriminative power are important for a cost-effective deployment of proton therapy for locally-advanced non-small cell lung cancer (NSCLC). We validated a model predicting lung toxicity 6 months after radiotherapy (RT) treatment.
Methods:
The model published by Appelt et al. (Acta Oncol 2014) was selected from a literature search. It relies on a review of radiation pneumonitis reports and retained the most important predictors, Mean Lung Dose (MLD) as dosimetric factor and 6 factors influencing the patient’s susceptibility: pre-existing pulmonary comorbidity, age>63 years, mid/inferior tumor location and sequential chemotherapy as risk factors, and current smoking and smoking history as protective factors. A dataset of 109 NSCLC patients treated at MAASTRO Clinic using 1.8 Gy fraction doses (two fractions per day) up to 79.2 Gy was studied. The required parameters were retrospectively collected together with the dyspnea endpoint (CTC 3.0 scoring) at baseline and at 6 months after RT. All treatments were performed using 3D-conformal RT techniques as it was the case in the study of Appelt et al. Odds ratios were calculated using logistic regression modelling.
Results:
19.3% of patients presented post RT dyspnea≥2. Our dataset confirmed current smoking and pulmonary comorbidity as prognostic factors for this endpoint, with similar odds ratios (OR = 0.28 (p = 0.02) and OR = 2.95 (p = 0.02), respectively). Tumor location OR was outside of the reported 95% CI. When predicting the change in dyspnea with respect to the baseline score (delta dyspnea≥1, prevalence of 18.6%), the two prognostic factors were not significant anymore (OR = 0.56 (p = 0.27) and OR = 0.47 (p = 0.21), respectively). Both factors exhibited strong correlation with the baseline patient status: worse baseline dyspnea is often a manifestation of existing comorbidities and it determines the probability to stop smoking. MLD was not associated with outcome in any of our models.
Conclusions:
It is crucial to consider delta toxicity endpoints in prediction modeling in order to obtain meaningful models reflecting radiotherapy outcome. Acknowledgement: This project has received funding from the EU under grant agreement no 601826 (REQUITE).
Clinical trial identification:
Legal entity responsible for the study:
KU Leuven
Funding:
EU
Disclosure:
All authors have declared no conflicts of interest.
-
+
Patient with early stage disease and compromised lung function (ID 27)
- Event: ELCC 2017
- Type: Multidisciplinary Tumour Board
- Track:
- Presentations: 3
- Moderators:A. Dingemans, P. Van Schil
- Coordinates: 5/07/2017, 14:45 - 16:15, Room A
-
+
Patient assessment and shared decision-making (ID 109)
14:45 - 16:15 | Author(s): D.R. Baldwin
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
The argument for SBRT (ID 111)
14:45 - 16:15 | Author(s): K. Franks
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
The case for limited surgery (ID 110)
14:45 - 16:15 | Author(s): A.D.L.D.L. Sihoe
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Rare thoracic malignancies (ID 14)
- Event: ELCC 2017
- Type: Specialty Session
- Track:
- Presentations: 4
- Moderators:P. Van Schil, F. Melfi
- Coordinates: 5/06/2017, 11:00 - 12:30, Room X
-
+
Diagnostic workup and treatment of bronchopulmonary carcinoid tumours (ID 60)
11:00 - 12:30 | Author(s): S. Schmid
- Abstract
Abstract not provided
-
+
Isolated lung perfusion for pulmonary metastases from sarcoma (ID 57)
11:00 - 12:30 | Author(s): P. Van Schil
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Local control in primary sarcoma of the chest wall (ID 58)
11:00 - 12:30 | Author(s): K. Wiebe
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Robotic extended thymectomy for early stage thymoma (ID 59)
11:00 - 12:30 | Author(s): F. Melfi
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
SCLC and early stage NSCLC (ID 62)
- Event: ELCC 2017
- Type: Proffered Paper session
- Track:
- Presentations: 7
- Moderators:S. Popat, P. Van Schil
- Coordinates: 5/07/2017, 09:00 - 10:30, Room C
-
+
Invited Discussant 44O, 59O and 60O (ID 545)
09:00 - 10:30 | Author(s): W.E.E. Eberhardt
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Invited Discussant 51O and LBA2_PR (ID 546)
09:00 - 10:30 | Author(s): S. Popat
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
44O - Validation of the prognostic value of 8th edition revisions of the AJCC staging system for non-small cell lung cancer: A SEER database analysis (ID 494)
09:00 - 10:30 | Author(s): O. Abdel-Rahman
- Abstract
- Presentation
Background:
The 8[th] edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study seeks to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database.
Methods:
SEER database (2010-2013) has been accessed through SEER*Stat program and AJCC 8[th] edition stages were reconstructed utilizing the collaborative stage descriptions. Overall and lung cancer-specific survival analyses according to both 7[th] and 8[th] editions were conducted through Kaplan-Meier analysis and multivariate analysis was conducted through a Cox proportional hazard model.
Results:
A total of 127096 patients with NSCLC were identified in the period from 2010-2013. For overall survival assessment according to the 8[th] edition, P values for all pair wise comparisons among different stages were significant (<0.0001) except for the comparison between stage IIA and stage IIB (P = 0.102). For lung cancer-specific survival according to the 8[th] edition, P values for all pair wise comparisons among different stages were significant (<0.0001). Among patients with stage I disease, multivariate analysis for factors affecting overall and lung cancer-specific survival among patients with stage I disease was conducted. The following factors were associated with worse overall and lung cancer-specific survival (age ≥ 70 years, more advanced stage, male gender, squamous histology, no surgery and no radiotherapy) (P < 0.0001 for all factors).
Conclusions:
This SEER analysis supports the prognostic significance of the added sub-stages described within AJCC 8[th] edition stages I and III. Further work is needed to incorporate molecular markers and personalize the future editions of the AJCC staging system.
Clinical trial identification:
Legal entity responsible for the study:
Omar Abdel-Rahman
Funding:
Omar Abdel-Rahman
Disclosure:
The author has declared no conflicts of interest.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
51O - Early limited-stage small cell lung cancer: Sub-group analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial (ID 474)
09:00 - 10:30 | Author(s): A. Salem, L. Ashcroft, A. Dagnault, C. de Metz, M. Hatton, I. Locke, I. Monnet, L. Padovani, F. Blackhall, C. Faivre-Finn
- Abstract
- Presentation
Background:
There is little evidence to guide the management of early limited-stage small cell lung cancer (LS-SCLC). We examined outcome of early LS-SCLC patients treated within a contemporary trial.
Methods:
This is an exploratory analysis of early (TNM stage I-II) LS-SCLC patients included in the CONVERT trial. This is a randomized phase III trial that compared twice-daily (45 Gray (Gy) in 30 twice-daily fractions over 3 weeks) and once-daily (66 Gy in 33 daily fractions over 6.5 weeks) radiotherapy starting on day 22 of chemotherapy cycle 1 in good performance score (PS) patients. Chemotherapy consisted of 4-6 cycles of cisplatin and etoposide. Prophylactic cranial irradiation (PCI) was offered if indicated. Radiotherapy was delivered using three-dimensional conformal or intensity modulated technique.
Results:
Between 2008 and 2013, 547 patients were recruited to this trial. Five hundred and thirteen patients were eligible for this analysis and 87 (17%) had early disease. Staging flurodeoxyglucose positron emission tomography (FDG-PET) use (68% versus 55.4%, p = 0.05) and baseline PS (PS0 57.5% versus 43.2%, p = 0.04) were different between early and non-early LS-SCLC patients, respectively. Early patients achieved longer overall survival (median 50 versus 25 months, p = 0.001) and time to local (median 40 versus 17 months, p = 0.0017) and metastatic progression (median 49 versus 16 months, p = 0.0004) compared to non-early patients, irrespective of treatment arm. In early patients, there was no significant overall survival difference between treatment arms, p = 0.31. Radiotherapy compliance was significantly higher in early patients (p = 0.004) and these patients were less likely to experience grade ≥3 acute oesophagitis, compared to non-early patients (11% versus 21%, p < 0.005).
Conclusions:
Early LS-SCLC patients achieve good long-term survival with minimal acute side-effects following chemo-radiotherapy and PCI. This study guides practice and provides a benchmark for future studies comparing a surgical to a non-surgical approach in this patient cohort.
Clinical trial identification:
ISRCTN91927162, NCT00433563
Legal entity responsible for the study:
MAHSC-CTU, The Christie NHS Foundation Trust, Manchester, UK
Funding:
Cancer Research UK
Disclosure:
All authors have declared no conflicts of interest.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
- Abstract
- Presentation
Background:
Epidermal growth factor receptor (EGFR) mutation represents a favorable prognostic factor in advanced-stage non-small cell lung cancer (NSCLC), which is predominantly contributed by its good response to EGFR-tyrosine kinase inhibitor. However, its impact on the prognosis of resectable NSCLC after complete surgery, which more closely reflects its natural course, remains controversial. Diverse results have been reported partially due to the small sample size of these studies; small studies bring bias especially in postoperative setting. Therefore, we sought to pool all current evidence to show the true effects.
Methods:
Electronic databases were searched for eligible studies. The primary endpoint was disease free survival (DFS), which will be less influenced by subsequent treatments after recurrence. The DFS between EGFR mutated and wild-type patients were compared with special interest in stage I patients who are rarely subjected to adjuvant therapy. In addition, DFS of patients with 19 exon deletion (19del) and 21 exon L858R mutation (L858R) were compared. Random effects models were used.
Results:
A total of 13 studies involving 2,652 cases were included; 1033 (39.0%) patients were EGFR-mutated, 47.7% were 19del and 44.1% were L858R. Most studies detected EGFR mutations with PCR-based methods. The DFS of EGFR-mutated patients were similar to wild type patients in overall population (HR 0.87, 95% CI 0.65 to 1.16) and stage I subgroup (HR 0.82, 95% CI 0.40 to 1.69). DFS of 19del patients was potentially inferior to L858R patients but the difference was not significant (HR 1.38, 95% CI 0.76 to 2.52).
Conclusions:
EGFR-mutated patients showed no significant difference in postoperative disease-free survival compared with wild-type resected NSCLC. There is still no sufficient evidence to support different postoperative treatment strategy (especially for stage I) for mutated and wild-type patients. However, 19del might be an adverse factor through indirect reasoning, which might require more intensive management. Thus, we strongly encouraged reporting specific prognostic impacts of different mutation types compared with wild-type patients in the following studies.
Clinical trial identification:
Legal entity responsible for the study:
The clinical research center of the first affiliated hospital of Guangzhou Medical Univeristy
Funding:
The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Disclosure:
All authors have declared no conflicts of interest.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
60O - The benchmark of examined lymph node count in node positive NSCLC patients: A populational validation with SEER database (ID 518)
09:00 - 10:30 | Author(s): W. Liang, J. He, G. Rocco, T. D’amico, C.S.H. Ng, A. Brunelli, C. Liu, R.H. Petersen, J. He
- Abstract
- Presentation
Background:
Based on SEER database and a Chinese multicenter registry, we previously identified a benchmark for indicating sufficient lymph node (LN) examination among node negative NSCLC patients (Liang et al. J Clin Oncol 2016). Due to variability of LN examination practice, some patients with less than 16 examined LNs might be understaged and therefore have worse survival outcome. This benchmark agrees with the reported mean LN being harvested during complete pulmonary and mediastinal LN exploration, which could serve as a sign for adequate systematic LN sampling and theorectically be applicable to node positive patients as well. We sought to determine its prognostic value among node positive patients using SEER database.
Methods:
The United States Surveillance, Epidemiology, and End Results (SEER) database on stage I to IIIA completely resected NSCLC (1990-2010) were extracted. Patients were dichotomized according to examined LN count (<16 vs. > =16). Multivariate Cox regression model was used to compare the overall survival (OS) and cancer specific survival (CSS) between groups under adjustment for other prognostic factor.
Results:
A total of 12,407 cases met the inclusion criteria with complete data were studied. The median followup was 7.6 years (range 0.1 to 10.0). Patients with <16 examined LNs remained a significant unfavorable factor in terms of both OS (HR 1.34, 95% CI 1.27 to 1.43, P < 0.001) and CSS (HR 1.36, 95% CI 1.27 to 1.45) when compared to those with at least 16 LNs, after adjusting for diagnostic year, sex, age, tumor size, differentiation, pathology and positive LN count. Different subgroups showed consistent trends.
Conclusions:
This study confirmed that 16 exmamined LNs could also be considered a benchmark for systematic LN examination among node positive NSCLC patients despite the number of positive LNs. Node positive NSCLC with less than 16 LNs being harvested should be cautiously evaluated for the quality of LN examination and indication for subsequent treatment.
Clinical trial identification:
Legal entity responsible for the study:
The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Funding:
The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Disclosure:
T. D’Amico: Consulting or Advisory Role: Scanlan International. C.S.H. Ng: Leadership: Johnson & Johnson; Honoraria: J&J, Covidien, Medtronic; Consulting or Advisory Role: J&J, Covidien, Medtronic; Speakers’ Bureau: J&J, Covidien, Medtronic; Research Funding: J&J, Covidien, Medtronic. A. Brunelli: Honoraria: Bard Medical. C-C. Liu: Honoraria: Johnson & Johnson Consulting or Advisory Role: Johnson & Johnson Travel, Accommodation, Expenses: Johnson & Johnson (I). R.H. Petersen: Honoraria: Medtronic, Ethicon, Medela. J. He: Consulting or Advisory Role: Johnson & Johnson. All other authors have declared no conflicts of interest.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
LBA2_PR - Use of G-CSF and prophylactic antibiotics with concurrent chemo-radiotherapy in limited-stage small cell lung cancer: Results from the Phase III CONVERT trial (ID 501)
09:00 - 10:30 | Author(s): F. Gomes, C. Faivre-Finn, F. Fernandez-Gutierrez, D. Ryder, A. Bezjak, F. Cardenal, P. Fournel, J. Van Meerbeeck, F. Blackhall
- Abstract
- Presentation
Background:
Concurrent chemo-radiotherapy (CTRT) is the optimal treatment for limited-stage small cell lung cancer. The use of granulocyte colony stimulating-factor (G-CSF) in this context is controversial and its routine use is not recommended after a report of higher toxicity but the safety data is scarce. The use of prophylactic antibiotics is also not standardised.
Methods:
In a phase 3 trial, 547 patients (pts) were randomised between once-daily RT (66Gy 33 fractions) or twice-daily (45Gy 30 fractions) with chemotherapy (cisplatin/etoposide). The use of prophylactic G-CSF and antibiotics was permitted.
Results:
33% of pts received at least 1 cycle of prophylactic G-CSF and 41% received prophylactic and/or therapeutic G-CSF. Its use increased from 11% at cycle 1 to 27% at cycle 4. Prophylactic antibiotics were used in 48% of pts but its use decreased from 41% to 20%. The use of antibiotics and/or G-CSF was similar in both arms. The incidence of grade 3/4 thrombocytopenia was higher in pts with G-CSF (29.4% vs. 13%; p
Conclusions:
The use of G-CSF with modern radiotherapy techniques during CTRT does not result in an increased risk of severe acute esophagitis or pneumonitis. Despite an increased incidence of severe thrombocytopenia and anaemia, the use of G-CSF was not detrimental in PFS or OS.
Clinical trial identification:
ISRCTN91927162 / NCT00433563
Legal entity responsible for the study:
The Christie NHS Foundation Trust
Funding:
The Christie NHS FT, Cancer Research UK, EORTC, GECP, GFPC, IFCT.
Disclosure:
All authors have declared no conflicts of interest.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
Author of
-
+
Imaging and locally advanced NSCLC (ID 41)
- Event: ELCC 2017
- Type: Poster Discussion session
- Track:
- Presentations: 1
- Moderators:H. Prosch, S. Senan, P. Van Schil
- Coordinates: 5/06/2017, 14:45 - 15:45, Room W
-
+
Invited Discussant 61PD and 72PD (ID 530)
14:45 - 15:45 | Author(s): P. Van Schil
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Rare thoracic malignancies (ID 14)
- Event: ELCC 2017
- Type: Specialty Session
- Track:
- Presentations: 1
- Moderators:P. Van Schil, F. Melfi
- Coordinates: 5/06/2017, 11:00 - 12:30, Room X
-
+
Isolated lung perfusion for pulmonary metastases from sarcoma (ID 57)
11:00 - 12:30 | Author(s): P. Van Schil
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
